• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Vector Group Reports Fourth Quarter and Full Year 2023 Financial Results

    2/13/24 4:30:00 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $VGR alert in real time by email

    Montego maintains position as largest discount brand in the U.S.

    Fourth Quarter 2023 Highlights:

    • Consolidated revenues of $360.4 million, down 0.9% or $3.4 million compared to the prior year period.
      • Tobacco segment wholesale market share increased to 5.7% from 5.5% in the prior year period and retail market share remained at 5.8% in the current period.
      • Montego wholesale market share increased to 3.8% from 3.0% in the prior year period and retail market share increased to 3.8% from 3.2% in the prior year period.
    • Operating income of $91.6 million, up 2.6% or $2.3 million compared to the prior year period.
      • Tobacco segment operating income of $98.1 million, up 5.6% or $5.2 million compared to the prior year period.
    • Adjusted EBITDA of $96.0 million, up 3.6% or $3.3 million compared to the prior year period.
      • Tobacco Adjusted EBITDA of $99.6 million, up 5.4% or $5.1 million compared to the prior year period.

    Full Year 2023 Highlights:

    • Consolidated revenues of $1.42 billion, down 1.2% or $16.7 million compared to the prior year.
      • Tobacco segment revenues of $1.42 billion, down 0.1% or $0.9 million compared to the prior year.
      • Tobacco segment wholesale and retail market share increased to 5.5% and 5.8% from 5.4% and 5.5%, respectively, in the prior year.
      • Montego wholesale market share increased to 3.5% from 2.5% in the prior year and retail market share increased to 3.6% from 2.6% in the prior year.
    • Operating income of $328.0 million, down 3.2% or $11.0 million compared to the prior year.
      • Tobacco segment operating income of $346.7 million, down 0.1% or $0.4 million compared to the prior year.
    • Adjusted EBITDA of $363.2 million, up 3.1% or $11.0 million compared to the prior year.
      • Tobacco Adjusted EBITDA of $370.6 million, up 5.5% or $19.4 million compared to the prior year.

     

    Vector Group Ltd. (NYSE:VGR) today announced financial results for the three months and year ended December 31, 2023.

    "Vector Group delivered a solid performance in 2023 amid a dynamic operating environment, as the successful execution of our targeted investment strategy enabled Montego's continued growth as the largest discount brand in the United States," said Howard M. Lorber, President and Chief Executive Officer of Vector Group Ltd. "The Company is well positioned in 2024 and we are confident we have the right strategy and team in place to continue optimizing long-term profit and driving value for our stockholders."

    GAAP Financial Results

    Three months ended December 31, 2023 and 2022. Fourth quarter 2023 revenues were $360.4 million, compared to $363.8 million in the fourth quarter of 2022. The Company recorded operating income of $91.6 million in the fourth quarter of 2023, compared to $89.3 million in the fourth quarter of 2022. Net income for the fourth quarter of 2023 was $58.0 million, or $0.37 per diluted common share, compared to $48.2 million, or $0.30 per diluted common share, in the fourth quarter of 2022.

    Year ended December 31, 2023 and 2022. For the year ended December 31, 2023, revenues were $1.42 billion, compared to $1.44 billion for the year ended December 31, 2022. The Company recorded operating income of $328.0 million for the year ended December 31, 2023, compared to $339.0 million for the year ended December 31, 2022. Net income for the year ended December 31, 2023 was $183.5 million, or $1.16 per diluted common share, compared to $158.7 million, or $1.01 per diluted common share, for the year ended December 31, 2022.

    Non-GAAP Financial Measures

    Three months ended December 31, 2023 compared to the three months ended December 31, 2022

    Adjusted EBITDA (as described in Table 2 attached hereto) were $96.0 million for the fourth quarter of 2023, compared to $92.7 million for the fourth quarter of 2022.

    Adjusted Net Income (as described in Table 3 attached hereto) was $57.5 million, or $0.36 per diluted share, for the fourth quarter of 2023, compared to $48.9 million, or $0.31 per diluted share, for the fourth quarter of 2022.

    Adjusted Operating Income (as described in Table 4 attached hereto) was $91.6 million for the fourth quarter of 2023, compared to $89.4 million for the fourth quarter of 2022.

    Year ended December 31, 2023 compared to the year ended December 31, 2022

    Adjusted EBITDA (as described in Table 2 attached hereto) were $363.2 million for the year ended December 31, 2023, compared to $352.2 million for the year ended December 31, 2022.

    Adjusted Net Income (as described in Table 3 attached hereto) was $194.3 million, or $1.23 per diluted share, for the year ended December 31, 2023, compared to $153.4 million, or $0.97 per diluted share, for the year ended December 31, 2022.

    Adjusted Operating Income (as described in Table 4 attached hereto) was $346.1 million for the year ended December 31, 2023, compared to $337.1 million for the year ended December 31, 2022.

    Consolidated Balance Sheet

    Vector Group maintained significant liquidity at December 31, 2023 with cash and cash equivalents of $268.6 million, including $16.8 million of cash from the Tobacco segment, investment securities of $110.9 million and long-term investments of $46.8 million.

    Vector Group continued its longstanding history of paying a quarterly cash dividend in the fourth quarter of 2023. For the year ended December 31, 2023, Vector Group returned a total of $127.0 million to stockholders at a quarterly rate of $0.20 per common share.

    Tobacco Segment Financial Results

    For the fourth quarter of 2023, the Tobacco segment had revenues of $360.4 million, compared to $363.8 million for the fourth quarter of 2022. For the year ended December 31, 2023, the Tobacco segment had revenues of $1.42 billion, compared to $1.43 billion for the year ended December 31, 2022.

    Operating Income from the Tobacco segment was $98.1 million and $346.7 million for the three months and year ended December 31, 2023, respectively, compared to $93.0 million and $347.0 million for the three months and the year ended December 31, 2022, respectively.

    Non-GAAP Financial Measures

    Tobacco Adjusted Operating Income (as described in Table 5 attached hereto) for the fourth quarter of 2023 was $98.1 million compared to $93.0 million for the fourth quarter of 2022. Tobacco Adjusted Operating Income for the year ended December 31, 2023 was $364.7 million, compared to $345.2 million for the year ended December 31, 2022.

    Operational Metrics

    For the fourth quarter of 2023, the Tobacco segment had conventional cigarette (wholesale) shipments of approximately 2.37 billion units, compared to 2.56 billion units for the fourth quarter of 2022. For the year ended December 31, 2023, the Tobacco segment had conventional cigarette (wholesale) shipments of approximately 9.69 billion units, compared to 10.35 billion units for the year ended December 31, 2022.

    According to data from Management Science Associates, Inc., for the fourth quarter of 2023, the Tobacco segment's wholesale market share increased to 5.7%, from 5.5% for the fourth quarter of 2022. For the year ended December 31, 2023, the Tobacco segment's wholesale market share increased to 5.5%, from 5.4% for the year ended December 31, 2022. For the fourth quarter of 2023, Montego's wholesale market share increased to 3.8%, from 3.0% for the fourth quarter of 2022. For the year ended December 31, 2023, Montego's wholesale market share increased to 3.5%, from 2.5% for the year ended December 31, 2022. The Tobacco segment's wholesale shipments in the fourth quarter of 2023 declined by 7.4% compared to the fourth quarter of 2022, while the industry's overall wholesale shipments declined by 9.5%. The Tobacco segment's wholesale shipments for the year ended December 31, 2023 declined by 6.2% compared to the year ended December 31, 2022, while the industry's overall wholesale shipments declined by 7.5%.

    According to data from Management Science Associates, Inc., for the fourth quarter of 2023, the Tobacco segment's retail market share remained at 5.8% compared to the fourth quarter of 2022. For the year ended December 31, 2023, the Tobacco segment's retail market share increased to 5.8%, from 5.5% for the year ended December 31, 2022. For the fourth quarter of 2023, Montego's retail market share increased to 3.8%, from 3.2% for the fourth quarter of 2022. For the year ended December 31, 2023, Montego's retail market share increased to 3.6%, from 2.6% for the year ended December 31, 2022. The Tobacco segment's retail shipments in the fourth quarter of 2023 declined by 8.4% compared to the fourth quarter of 2022, while the industry's overall retail shipments declined by 8.5%. The Tobacco segment's retail shipments for the year ended December 31, 2023 declined by 3.4% compared to the year ended December 31, 2022, while the industry's overall retail shipments declined by 8.3%.

    Non-GAAP Financial Measures

    Adjusted EBITDA, Adjusted Net Income, Adjusted Operating Income, Tobacco Adjusted Operating Income and Tobacco Adjusted EBITDA (the "Non-GAAP Financial Measures") are financial measures not prepared in accordance with generally accepted accounting principles ("GAAP"). The Company believes that the Non-GAAP Financial Measures are important measures that supplement discussions and analysis of its results of operations and enhance an understanding of its operating performance. The Company believes the Non-GAAP Financial Measures provide investors and analysts with a useful measure of operating results unaffected by differences in capital structures and ages of related assets among otherwise comparable companies.

    Management uses the Non-GAAP Financial Measures as measures to review and assess operating performance of the Company's business, and management does and investors should review both the overall performance (GAAP net income) and the operating performance (the Non-GAAP Financial Measures) of the Company's business. While management considers the Non-GAAP Financial Measures to be important, they should be considered in addition to, but not as substitutes for or superior to, other measures of financial performance prepared in accordance with GAAP, such as operating income, net income and cash flows from operations. In addition, the Non-GAAP Financial Measures are susceptible to varying calculations and the Company's measurement of the Non-GAAP Financial Measures may not be comparable to those of other companies.

    Reconciliations of Non-GAAP Financial Measures to the comparable GAAP financial results for the fourth quarter and full year ended December 31, 2023 and 2022 are included in Tables 2 through 5.

    Conference Call to Discuss Fourth Quarter and Full Year 2023 Results

    As previously announced, the Company will host a conference call and webcast on Wednesday, February 14, 2024 at 8:00 AM (ET) to discuss its fourth quarter and full year results. Investors may access the call via live webcast at https://www.webcaster4.com/Webcast/Page/2271/49823. Please join the webcast at least ten minutes prior to the start time.

    A replay of the call will be available shortly after the call ends on February 14, 2024 through February 28, 2024 at https://www.webcaster4.com/Webcast/Page/2271/49823.

    About Vector Group Ltd.

    Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC, and New Valley LLC. Additional information concerning the Company is available on the Company's website, www.VectorGroupLtd.com.

    Investors and others should note that we may post information about the Company or its subsidiaries on our website at www.VectorGroupLtd.com and/or at the websites of those subsidiaries or, if applicable, on their accounts on LinkedIn, Twitter or other social media platforms. It is possible that the postings or releases could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.VectorGroupLtd.com, on the websites of our subsidiaries and on their social media accounts.

    Forward-Looking and Cautionary Statements

    This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "estimate," "expect," "intend," "may be," "continue," "could," "potential," "objective," "plan," "seek," "predict," "project" and "will be" and similar words or phrases or their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual results could differ materially for a variety of reasons.

    Risks and uncertainties that could cause our actual results to differ significantly from our current expectations are described in our Annual Report on Form 10-K for the year ended December 31, 2022 and, when filed, in our Annual Report on Form 10-K for the year ended December 31, 2023. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.

    [Financial Tables Follow]

    TABLE 1

    VECTOR GROUP LTD. AND SUBSIDIARIES

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited)

    (Dollars in Thousands, Except Per Share Amounts)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenues:

     

     

     

     

     

     

     

    Tobacco*

    $

    360,350

     

     

    $

    363,770

     

     

    $

    1,424,268

     

     

    $

    1,425,125

     

    Real estate

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    15,884

     

    Total revenues

     

    360,350

     

     

     

    363,770

     

     

     

    1,424,268

     

     

     

    1,441,009

     

     

     

     

     

     

     

     

     

    Expenses:

     

     

     

     

     

     

     

    Cost of sales:

     

     

     

     

     

     

     

    Tobacco*

     

    238,398

     

     

     

    247,582

     

     

     

    965,348

     

     

     

    991,331

     

    Real estate

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    7,327

     

    Total cost of sales

     

    238,398

     

     

     

    247,582

     

     

     

    965,348

     

     

     

    998,658

     

     

     

     

     

     

     

     

     

    Operating, selling, administrative and general expenses

     

    30,352

     

     

     

    26,837

     

     

     

    112,086

     

     

     

    103,102

     

    Litigation settlement and judgment expense

     

    10

     

     

     

    79

     

     

     

    18,799

     

     

     

    239

     

    Operating income

     

    91,590

     

     

     

    89,272

     

     

     

    328,035

     

     

     

    339,010

     

     

     

     

     

     

     

     

     

    Other income (expenses):

     

     

     

     

     

     

     

    Interest expense

     

    (26,763

    )

     

     

    (27,245

    )

     

     

    (108,617

    )

     

     

    (110,665

    )

    (Loss) gain on extinguishment of debt

     

    (368

    )

     

     

    —

     

     

     

    (549

    )

     

     

    412

     

    Equity in earnings (losses) from investments

     

    1,403

     

     

     

    177

     

     

     

    1,262

     

     

     

    (4,995

    )

    Equity in (losses) earnings from real estate ventures

     

    (2,598

    )

     

     

    (1,706

    )

     

     

    2,202

     

     

     

    (5,946

    )

    Other, net

     

    10,601

     

     

     

    7,789

     

     

     

    26,119

     

     

     

    2,746

     

    Income before provision for income taxes

     

    73,865

     

     

     

    68,287

     

     

     

    248,452

     

     

     

    220,562

     

    Income tax expense

     

    15,868

     

     

     

    20,137

     

     

     

    64,926

     

     

     

    61,861

     

     

     

     

     

     

     

     

     

    Net income

    $

    57,997

     

     

    $

    48,150

     

     

    $

    183,526

     

     

    $

    158,701

     

     

     

     

     

     

     

     

     

    Per basic common share:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net income applicable to common shares

    $

    0.37

     

     

    $

    0.30

     

     

    $

    1.17

     

     

    $

    1.01

     

     

     

     

     

     

     

     

     

    Per diluted common share:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net income applicable to common shares

    $

    0.37

     

     

    $

    0.30

     

     

    $

    1.16

     

     

    $

    1.01

     

    * Revenues and cost of sales include federal excise taxes of $118,752, $128,756, $486,263 and $520,760 for the three months and year ended December 31, 2023 and 2022, respectively.

    TABLE 2

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF ADJUSTED EBITDA

    (Unaudited)

    (Dollars in Thousands)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Net income

    $

    57,997

     

     

    $

    48,150

     

     

    $

    183,526

     

     

    $

    158,701

     

    Interest expense

     

    26,763

     

     

     

    27,245

     

     

     

    108,617

     

     

     

    110,665

     

    Income tax expense

     

    15,868

     

     

     

    20,137

     

     

     

    64,926

     

     

     

    61,861

     

    Depreciation and amortization

     

    1,756

     

     

     

    1,788

     

     

     

    6,941

     

     

     

    7,218

     

    EBITDA

    $

    102,384

     

     

    $

    97,320

     

     

    $

    364,010

     

     

    $

    338,445

     

    Equity in (earnings) losses from investments (a)

     

    (1,403

    )

     

     

    (177

    )

     

     

    (1,262

    )

     

     

    4,995

     

    Equity in losses (earnings) from real estate ventures (b)

     

    2,598

     

     

     

    1,706

     

     

     

    (2,202

    )

     

     

    5,946

     

    Loss (gain) on extinguishment of debt

     

    368

     

     

     

    —

     

     

     

    549

     

     

     

    (412

    )

    Stock-based compensation expense (c)

     

    2,687

     

     

     

    1,573

     

     

     

    10,111

     

     

     

    7,848

     

    Litigation settlement and judgment expense (d)

     

    10

     

     

     

    79

     

     

     

    18,799

     

     

     

    239

     

    Impact of MSA settlement (e)

     

    —

     

     

     

    —

     

     

     

    (734

    )

     

     

    (2,123

    )

    Other, net

     

    (10,601

    )

     

     

    (7,789

    )

     

     

    (26,119

    )

     

     

    (2,746

    )

    Adjusted EBITDA

    $

    96,043

     

     

    $

    92,712

     

     

    $

    363,152

     

     

    $

    352,192

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA by Segment

     

     

     

     

     

     

     

    Tobacco

    $

    99,625

     

     

    $

    94,540

     

     

    $

    370,575

     

     

    $

    351,131

     

    Real Estate

     

    19

     

     

     

    177

     

     

     

    313

     

     

     

    8,082

     

    Corporate and Other

     

    (3,601

    )

     

     

    (2,005

    )

     

     

    (7,736

    )

     

     

    (7,021

    )

    Total

    $

    96,043

     

     

    $

    92,712

     

     

    $

    363,152

     

     

    $

    352,192

     

    __________________

    a.

    Represents equity in (earnings) losses recognized from investments that the Company accounts for under the equity method.

    b.

    Represents equity in losses (earnings) recognized from the Company's investment in certain real estate ventures that are accounted for under the equity method and are not consolidated in the Company's financial results.

    c.

    Represents amortization of stock-based compensation.

    d.

    Represents accruals for litigation in the Tobacco segment.

    e.

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

    TABLE 3

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF ADJUSTED NET INCOME

    (Unaudited)

    (Dollars in Thousands, Except Per Share Amounts)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Net income

    $

    57,997

     

     

    $

    48,150

     

     

    $

    183,526

     

     

    $

    158,701

     

     

     

     

     

     

     

     

     

    Loss (gain) on extinguishment of debt

     

    368

     

     

     

    —

     

     

     

    549

     

     

     

    (412

    )

    Litigation settlement and judgment expense (a)

     

    10

     

     

     

    79

     

     

     

    18,799

     

     

     

    239

     

    Impact of MSA settlement (b)

     

    —

     

     

     

    —

     

     

     

    (734

    )

     

     

    (2,123

    )

    Impact of net interest expense capitalized to real estate ventures

     

    (1,161

    )

     

     

    955

     

     

     

    (4,204

    )

     

     

    (2,137

    )

    Expense related to Tax Disaffiliation indemnification (c)

     

    —

     

     

     

    8

     

     

     

    —

     

     

     

    589

     

    Adjustment for derivative associated with guarantee

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (2,646

    )

    Total adjustments

     

    (783

    )

     

     

    1,042

     

     

     

    14,410

     

     

     

    (6,490

    )

     

     

     

     

     

     

     

     

    Tax expense (benefit) related to adjustments

     

    284

     

     

     

    (267

    )

     

     

    (3,637

    )

     

     

    1,144

     

     

     

     

     

     

     

     

     

    Adjusted Net Income

    $

    57,498

     

     

    $

    48,925

     

     

    $

    194,299

     

     

    $

    153,355

     

     

     

     

     

     

     

     

     

    Per diluted common share:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted Net Income applicable to common shares

    $

    0.36

     

     

    $

    0.31

     

     

    $

    1.23

     

     

    $

    0.97

     

    __________________

    a.

    Represents accruals for litigation in the Tobacco segment.

    b.

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

    c.

    Represents amounts accrued under the Company's Tax Disaffiliation Agreement related to certain tax liabilities of Douglas Elliman Inc. prior to its distribution on December 29, 2021.

    TABLE 4

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF ADJUSTED OPERATING INCOME

    (Unaudited)

    (Dollars in Thousands)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

    2023

     

    2022

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Operating income

    $

    91,590

     

    $

    89,272

     

    $

    328,035

     

     

    $

    339,010

     

     

     

     

     

     

     

     

     

    Litigation settlement and judgment expense (a)

     

    10

     

     

    79

     

     

    18,799

     

     

     

    239

     

    Impact of MSA settlement (b)

     

    —

     

     

    —

     

     

    (734

    )

     

     

    (2,123

    )

    Total adjustments

     

    10

     

     

    79

     

     

    18,065

     

     

     

    (1,884

    )

     

     

     

     

     

     

     

     

    Adjusted Operating Income

    $

    91,600

     

    $

    89,351

     

    $

    346,100

     

     

    $

    337,126

     

    __________________

    a.

    Represents accruals for litigation in the Tobacco segment.

    b.

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

    TABLE 5

    VECTOR GROUP LTD. AND SUBSIDIARIES

    RECONCILIATION OF TOBACCO ADJUSTED OPERATING INCOME

    AND TOBACCO ADJUSTED EBITDA

    (Unaudited)

    (Dollars in Thousands)

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

    2023

     

    2022

     

     

    2023

     

     

     

    2022

     

     

     

     

     

    Tobacco Adjusted Operating Income:

     

     

     

     

     

     

     

    Operating income from Tobacco segment

    $

    98,131

     

    $

    92,966

     

    $

    346,673

     

     

    $

    347,044

     

     

     

     

     

     

     

     

     

    Litigation settlement and judgment expense (a)

     

    10

     

     

    79

     

     

    18,799

     

     

     

    239

     

    Impact of MSA settlement (b)

     

    —

     

     

    —

     

     

    (734

    )

     

     

    (2,123

    )

    Total adjustments

     

    10

     

     

    79

     

     

    18,065

     

     

     

    (1,884

    )

     

     

     

     

     

     

     

     

    Tobacco Adjusted Operating Income

    $

    98,141

     

    $

    93,045

     

    $

    364,738

     

     

    $

    345,160

     

     

    Three Months Ended

     

    Year Ended

     

    December 31,

     

    December 31,

     

    2023

     

    2022

     

     

    2023

     

     

     

    2022

     

     

     

     

     

     

     

     

     

    Tobacco Adjusted EBITDA:

     

     

     

     

     

     

     

    Operating income from Tobacco segment

    $

    98,131

     

    $

    92,966

     

    $

    346,673

     

     

    $

    347,044

     

     

     

     

     

     

     

     

     

    Litigation settlement and judgment expense (a)

     

    10

     

     

    79

     

     

    18,799

     

     

     

    239

     

    Impact of MSA settlement (b)

     

    —

     

     

    —

     

     

    (734

    )

     

     

    (2,123

    )

    Total adjustments

     

    10

     

     

    79

     

     

    18,065

     

     

     

    (1,884

    )

     

     

     

     

     

     

     

     

    Tobacco Adjusted Operating Income

     

    98,141

     

     

    93,045

     

     

    364,738

     

     

     

    345,160

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

    1,443

     

     

    1,475

     

     

    5,686

     

     

     

    5,901

     

    Stock-based compensation expense

     

    41

     

     

    20

     

     

    151

     

     

     

    70

     

    Total adjustments

     

    1,484

     

     

    1,495

     

     

    5,837

     

     

     

    5,971

     

     

     

     

     

     

     

     

     

    Tobacco Adjusted EBITDA

    $

    99,625

     

    $

    94,540

     

    $

    370,575

     

     

    $

    351,131

     

    __________________

    a.

    Represents accruals for litigation in the Tobacco segment.

    b.

    Represents the Tobacco segment's settlement of long-standing disputes related to the Master Settlement Agreement.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240213665895/en/

    Get the next $VGR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VGR

    DatePrice TargetRatingAnalyst
    3/31/2022$12.00 → $16.00Equal Weight → Overweight
    Barclays
    11/15/2021$13.00 → $17.00Underweight → Equal Weight
    Barclays
    11/9/2021$18.00Perform → Outperform
    Oppenheimer
    9/13/2021$15.00 → $13.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Health Set to Join S&P SmallCap 600

      NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

      10/4/24 6:05:00 PM ET
      $HIMS
      $SPGI
      $VGR
      Medical/Nursing Services
      Health Care
      Finance: Consumer Services
      Finance
    • Vector Group Announces Agreement to be Acquired by JT Group

      Delivers significant value for stockholders while positioning Vector Group for long-term success Vector Group Ltd. (NYSE:VGR) today announced that it has entered into a definitive agreement to be acquired by JT Group, a global company headquartered in Tokyo, Japan, operating in tobacco, pharmaceuticals and processed food. JT Group's global tobacco business, headquartered in Geneva, Switzerland, manufactures and sells some of the world's best-known brands in over 130 markets worldwide – including Winston and Camel (outside the U.S.), as well as MEVIUS and LD. Under the terms of the agreement, JT Group will offer to acquire all outstanding shares of Vector Group common stock for $15.00 pe

      8/21/24 6:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Declares Quarterly Cash Dividend

      Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

      8/20/24 3:08:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Financials

    Live finance-specific insights

    See more
    • Vector Group Declares Quarterly Cash Dividend

      Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

      8/20/24 3:08:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Reports Second Quarter 2024 Financial Results

      Montego maintains position as largest discount brand in the U.S. Second Quarter 2024 Highlights: Consolidated revenues of $371.9 million, up 1.7% or $6.3 million compared to the prior year period. Tobacco segment wholesale market share increased to 5.7% from 5.4% in the prior year period and retail market share remained at 5.8%, unchanged from the prior year period. Montego wholesale and retail market share both increased to 4.1% from 3.4% and 3.5%, respectively, in the prior year period. Operating income of $97.8 million, up 36.5% or $26.1 million compared to the prior year period. Tobacco segment operating income of $102.9 million, up 37.0% or $27.8 million compared to t

      7/31/24 4:45:00 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group to Host Second Quarter 2024 Results Conference Call

      Vector Group Ltd. (NYSE:VGR) will conduct a conference call and webcast to discuss its second quarter 2024 results on Thursday, August 1, 2024 at 8:00 a.m. (ET). Investors may access the call via live webcast at https://www.webcaster4.com/Webcast/Page/2271/50954. Please join the webcast at least 10 minutes prior to start time. A replay of the call will be available shortly after the call ends on August 1, 2024 through August 15, 2024 at https://www.webcaster4.com/Webcast/Page/2271/50954. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.

      7/25/24 8:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Health Set to Join S&P SmallCap 600

      NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

      10/4/24 6:05:00 PM ET
      $HIMS
      $SPGI
      $VGR
      Medical/Nursing Services
      Health Care
      Finance: Consumer Services
      Finance
    • Douglas Elliman Appoints Richard Ferrari as President and CEO of Brokerage for New York City and the Northeast Region

      Yuval Greenblatt and Alfred Renna Promoted to Senior Managing Director of Operations and Senior Managing Director of Sales, Respectively, for Flagship 575 Madison Avenue Office Douglas Elliman, one of the largest residential real estate brokerages in the United States, announced today that real estate veteran Richard Ferrari has joined the firm as President and CEO of Brokerage for New York City and the Northeast Region. In this role, Ferrari, a highly regarded industry expert, will oversee the firm's New York City resale markets, including Manhattan, Brooklyn, Riverdale and Long Island City in Queens. He will also assume responsibility for Elliman's New Jersey, Westchester, Connecticut a

      7/21/21 8:30:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group Appoints Technology Veteran Wilson L. White to its Board of Directors

      Expands Board to 10 Directors with Addition of Silicon Valley Executive Vector Group Ltd. (NYSE:VGR) (the "Company") today announced that it has appointed technology industry veteran, Wilson L. White, to its Board of Directors, effective immediately. Mr. White currently serves as Senior Director of Government Affairs and Public Policy at Google. With Mr. White's appointment, Vector Group's Board expands to 10 directors. "With many years of experience in the technology industry, including government relations and legal expertise, Wilson brings to the Board a unique skillset that will further strengthen Vector Group's commitment to staying at the forefront of our business' rapidly-evolving

      6/22/21 8:00:00 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vector Grp upgraded by Barclays with a new price target

      Barclays upgraded Vector Grp from Equal Weight to Overweight and set a new price target of $16.00 from $12.00 previously

      3/31/22 7:41:06 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Grp upgraded by Barclays with a new price target

      Barclays upgraded Vector Grp from Underweight to Equal Weight and set a new price target of $17.00 from $13.00 previously

      11/15/21 8:00:05 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Vector Group upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Vector Group from Perform to Outperform and set a new price target of $18.00

      11/9/21 6:13:20 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vector Group Ltd.

      15-12G - VECTOR GROUP LTD (0000059440) (Filer)

      10/17/24 8:00:07 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Vector Group Ltd.

      EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

      10/8/24 12:15:04 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Vector Group Ltd.

      EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

      10/8/24 12:15:08 AM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/15/24 4:00:16 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/7/24 8:43:24 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

      SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

      10/1/24 4:27:47 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care

    $VGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Watkins Barry returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:41:06 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Bell Marc N was granted 164,500 shares and returned $5,100,000 worth of shares to the company (340,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:14:02 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Sharpe Jean E returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

      4 - VECTOR GROUP LTD (0000059440) (Issuer)

      10/7/24 9:08:43 PM ET
      $VGR
      Medicinal Chemicals and Botanical Products
      Health Care